Form 4: Adaptive Biotechnologies CFO Kyle Piskel Reports Stock Transactions
SEC Form 4 Filing
Chief Financial Officer Kyle Piskel of Adaptive Biotechnologies Corp. reports acquisition and disposition of company stock to cover tax obligations.
Summary
- On May 15, 2025, Kyle Piskel, CFO of Adaptive Biotechnologies, acquired 7,815 shares of common stock.
- These shares were acquired at a price of $0.
- On May 16, 2025, Piskel sold 1,929 shares of common stock at $8.89 per share.
- The sale was to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
- Following these transactions, Piskel directly owns 277,396 shares of Adaptive Biotechnologies common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing relates to routine stock transactions for tax purposes.
Industry Context
This is a routine disclosure related to executive compensation and tax obligations, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Acquisition of 7,815 shares of common stock. |
| 05/16/2025 | Sale of 1,929 shares of common stock at $8.89 per share. |
| 05/19/2025 | Date of signature for the Form 4 filing. |
Keywords
Adaptive Biotechnologies, ADPT, Kyle Piskel, CFO, stock transaction, Form 4, RSU vesting, tax withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.